Jonathan Symonds Acquires 1,350 Shares of GSK plc (LON:GSK) Stock

GSK plc (LON:GSK) insider Jonathan Symonds purchased 1,350 shares of the stock in a transaction on Friday, June 20th. The shares were purchased at an average price of GBX 1,435 ($19.53) per share, with a total value of £19,372.50 ($26,371.49).

GSK Stock Performance

Shares of GSK stock opened at GBX 1,410 ($19.19) on Wednesday. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. GSK plc has a 52 week low of GBX 1,242.50 ($16.91) and a 52 week high of GBX 1,678.68 ($22.85). The firm’s 50 day moving average is GBX 1,431.05 and its two-hundred day moving average is GBX 1,414.31. The firm has a market capitalization of £57.22 billion, a P/E ratio of 22.78, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last posted its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.61) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Research analysts forecast that GSK plc will post 175.980975 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GSK has been the topic of a number of analyst reports. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Friday, March 28th. Shore Capital reissued a “buy” rating on shares of GSK in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of GBX 1,862.50 ($25.35).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.